NEW YORK, NY, Sep 3, 2013
- Phase II Program in Multiple Sclerosis and Inflammatory Bowel Disease
- Topline Data Expected in Mid-2014
- Available for Download at http://www.lifesciadvisors.com/clients/receptos/
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Receptos Inc. (NASDAQ: RCPT), a biopharmaceutical company developing treatments for immune diseases. Receptos is conducting Phase II clinical trials with lead candidate RPC1063 in multiple sclerosis (MS) and inflammatory bowel disease (IBD) patients, two markets that exceed $15 billion, and topline results are expected in mid-2014. RPC1063 is an oral S1PR modulator with several distinct potential advantages over existing S1PR modulators, such as Gilenya®, and has an improved safety profile while maintaining strong immunomodulation properties.
"Today's MS market is incredibly dynamic as patients cycle between therapies to seek relief from relapses and to limit treatment-related side effects," said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "As oral drugs begin to emerge and become the preferred treatment option, RPC1063 has the potential to tap into a significant portion of the market."
Receptos has significantly de-risked the RPC1063 program by developing a drug with superior safety and pharmacokinetic properties to other S1PR modulators either on the market or in development. The validation of this drug class through the approval of Gilenya® makes the path to market clear and feasible. Targeting patients with IBD, in addition to MS, gives Receptos access to a set of patients that have few viable treatment options. Receptos has a balanced portfolio of drug candidates, including two preclinical programs, setting the stage for continued milestones over the next several years.
In a 54 page Initiation Report by LifeSci Advisors, we explain the development path going forward for Receptos' programs. The report discusses the competitive advantages of RPC1063 over other S1PR modulators and how these advantages position the drug within the marketplace. We highlight the dynamic nature of the multiple sclerosis market and the strong potential for oral treatments in the future. We also discuss the application of RPC1063 in patients with inflammatory bowel disease, and the strong preclinical programs in development by Receptos.
Dr. McDonald's full Initiation Report is available to download at no cost at the LifeSci Advisors website, www.lifesciadvisors.com. In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-Head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.
About LifeSci Advisors:
LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website, www.lifesciadvisors.com.
The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.
Phone: (646) 597-6979
SOURCE: LifeSci Advisors